Shipping services continue despite COVID-19 outbreak ! Click here to view COVID-19 related products

SCH772984

For research use only.

Catalog No.S7101

328 publications

SCH772984 Chemical Structure

CAS No. 942183-80-4

SCH772984 is a novel, specific inhibitor of ERK1/2 with IC50 values of 4 nM and 1 nM in cell-free assay, respectively, And show robust efficacy in RAS- or BRAF-mutant cancer cells.

Size Price Stock Quantity  
USD 270 In stock
USD 1349 In stock
USD 5390 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's SCH772984 has been cited by 328 publications

Purity & Quality Control

Choose Selective ERK Inhibitors

Biological Activity

Description SCH772984 is a novel, specific inhibitor of ERK1/2 with IC50 values of 4 nM and 1 nM in cell-free assay, respectively, And show robust efficacy in RAS- or BRAF-mutant cancer cells.
Features Does not directly inhibit MEK1, MEK2, BRAF, or CRAF enzyme activity.
Targets
ERK2 [1]
(Cell-free assay)
ERK1 [1]
(Cell-free assay)
1 nM 4 nM
In vitro

SCH772984 is a novel, selective and ATP competitive inhibitor of ERK1/2. SCH772984 inhibits phosphorylation of the ERK substrate p90 ribosomal S6 kinase (T359/S363 phospho-RSK) in a dose-dependent manner. SCH772984 also inhibits phosphorylation of residues in the activation loop of ERK itself. SCH772984 demonstrates EC50 values <500 nM in approximately 88% and 49% of BRAF-mutant or RAS-mutant tumor lines, respectively. Importantly, SCH772984 effectively inhibited MAPK signaling and cell proliferation in tumor cells resistant to concurrent treatment with BRAF and MEK inhibitors. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
2P-ERK2 M{[zd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33OXGlEPTB;MD6yOEBvVQ>? NYrUemc4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzOVA6OzFpPkK1N|UxQTNzPD;hQi=>
WM-266-4 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoKyTWM2OD1{MDDuUS=> NVf4V2RCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
UACC-62 Mlv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4q2dGlEPTB;M{Cgcm0> MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
Colo-205 NVfjOY9OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PPOmlEPTB;M{[gcm0> MnLVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
SK-Mel-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{X4O2lEPTB;M{egcm0> MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
WiDr Mk\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkD4TWM2OD1|OTDuUS=> MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
M14 NUP3NlJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoX0TWM2OD12NzDuUS=> NIDhXXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
HT-29 M{O5RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zuc2lEPTB;NUCgcm0> MojrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
8505C NVniXld4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPITWM2OD13MDDuUS=> MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
HT-144 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fKcWlEPTB;NkCgcm0> M{fVXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
SK-Mel-5 Mn;hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXiZopqUUN3ME22OkBvVQ>? Mk\1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
A375-SM MoXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7TTWM2OD15NTDuUS=> MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
SK-Mel-28 NV3nNnFpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Lob2lEPTB;OEWgcm0> MnXTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
LOX NH3TNlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzOO3BQUUN3ME2xNFAhdk1? MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
SK-Mel-3 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;tTWM2OD1zMUigcm0> MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
K1 MoHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XqSmlEPTB;MUOwJI5O NUfBXJNTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
Hs-695T NYjsWoxzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHi4T49KSzVyPUG2OUBvVQ>? MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
BHT-101 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoqzTWM2OD1|MECgcm0> MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
RPMI-7951 M{X2TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLuO2w2UUN3ME2zOFQhdk1? M{f3[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
A2058 MofjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjTb|NzUUN3ME2zOlAhdk1? NUXK[GRDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
SK-Hep-1 NITucmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fhZmlEPTB;MUSyNkBvVQ>? MnHwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
A673 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTNyMEGgcm0> NYnDRolWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
DBTRG-05MG MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LifWlEPTB;M{CwNUBvVQ>? NEnnNYU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
SW-626 Mo[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2iyVGlEPTB;M{Ogcm0> Mmf3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
LoVo M4DsUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTR5IH7N NFi1Vmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
MiaPaCa NWf2VFdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTV|IH7N MoD5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
SW-620 M{DP[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHj0XVhKSzVyPUGwOEBvVQ>? NHXiTpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
CAPAN-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3lOWZKSzVyPUGwOEBvVQ>? Mmi2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
SW-527 Mlq2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2GxdmlEPTB;MUKxJI5O MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
HCT-116 NIm4VoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DFVWlEPTB;MUK4JI5O NIXzW4Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
SW-480 NE\aV5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTF4NTDuUS=> MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
HPAC NEPZO|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTF5MDDuUS=> MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
OVCAR-5 M2DrRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoL5TWM2OD1{MEigcm0> NXrhR3I5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
AsPc-1 M2jBZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHyTWM2OD1{N{Cgcm0> NWrrT|dGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
A549 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTN{NjDuUS=> NIn3WJc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
SNU-1 NX6yXmI4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlm5TWM2OD1|NUSgcm0> M4TOe|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
HOP62 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFG1S2VKSzVyPU[3OkBvVQ>? M2fkTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
H23 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTFyMECgcm0> MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
MB-231 NIS2OWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnz[HA1UUN3ME2xNFAxKG6P MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
SU.86.86 M2\DTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2OxPGlEPTB;MUCwNUBvVQ>? MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
CFPAC-1 MnPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXqNXlbUUN3ME2xNFAyKG6P MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
A427 MkL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXIXolKSzVyPUG0N|Mhdk1? NUTudGpCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
MDAH-2774 Ml;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHoTI5KSzVyPUK2OVchdk1? MnjTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
NCI-H157 M4jocGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPFTWM2OD1|MECwJI5O NWT6c2xRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
HTB-177 NV2xT4x5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTNyMECgcm0> MkW4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
UM-UC-3 M2izNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLCUHY1UUN3ME2zNFAyKG6P M{f3fFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
HCT-8 M4DtOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPIR45KSzVyPUOwNFEhdk1? MoLUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
Panc-1 M{PCemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrYS21KSzVyPUOwNFEhdk1? Mn;MQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
DLD-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fjNmlEPTB;M{CwNUBvVQ>? M3u0clxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
HCT-15 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHUTWM2OD1|MECxJI5O Ml7hQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
HL-60 Mn3PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTNyIH7N NYLLe5kyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
SK-Mel-2 NWXPSYpOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTN2IH7N MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
RD MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\yNWlEPTB;MUKzJI5O MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
HT-1197 M4\OeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnteIZKSzVyPUOxOkBvVQ>? NED0eFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
Molt-3 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXvTWM2OD14MECgcm0> NX\RWYR[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
PA-1 M3noe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlnVTWM2OD1zMECxJI5O MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
Molt-4 M{HWNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml[xTWM2OD1|MECxJI5O MlrqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
NCI-H292 NFfKbohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{T0NWlEPTB;OUCgcm0> NXPqcZY4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
A2780 NYXIUVRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvQ[HpmUUN3ME2xOFMhdk1? NFewSJc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
IGROV-1 M{jiSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGP6R|JKSzVyPUG0OkBvVQ>? M1vhc|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
SK-N-SH MkTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;XPGpuUUN3ME2xOVAhdk1? NEfCW3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
N-87 NHnOO4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnf1TWM2OD1|MEegcm0> M3XhRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
H322 MnnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TabmlEPTB;M{K1JI5O NF;NRmw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
H716 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDjTWM2OD1|M{Sgcm0> M1[0bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
TT NUK0TZd4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTRyNjDuUS=> M4KzNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
Caki-1 M2TOXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\CbnVKSzVyPUS1NEBvVQ>? MlzqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
5637 MlPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\mNmlEPTB;NkGwJI5O MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
MB-453 NI\QfpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;xcJR3UUN3ME22O|Ihdk1? MoXkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
RT-4 NYTmbFhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRThzMDDuUS=> M4ewTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
HOP92 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTh{MDDuUS=> NVLNVnhbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
KG-1 NYHP[GlZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTlyMDDuUS=> MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
Hs-294T NI\3d21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\oTWM2OD17NEWgcm0> NHXZTXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
SF-539 NXG2cVJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LQbGlEPTB;MUCwNEBvVQ>? M{LXVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
U-251 M3\mTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vPe2lEPTB;MUCwNEBvVQ>? MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
MB-468 Mmq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTFyMECgcm0> NXvIXmNnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
HS746T NXfnZY5vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3z6TGlEPTB;MUCwNEBvVQ>? MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
SCABER MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTFyMECgcm0> NXT3bYxqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
MCF-7 NFmwTVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvMd2tWUUN3ME2xNFAyKG6P MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
CHL-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXRbXN{UUN3ME2xOFYxKG6P MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
U87MG NX6zd3BRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4f1O2lEPTB;MkCwNEBvVQ>? MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
SJCRH30 MmjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVW0O2ZqUUN3ME2yNFAzKG6P NXP6VXE2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
ES-2 M{PaRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDaTWM2OD1{NkW5JI5O NFnUb5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
HT-1376 Mn3vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUCwbZJYUUN3ME2yPFAxKG6P NYrOPHAyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
A172 NYi2dmZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;VSnBKSzVyPUOwNFAhdk1? M{DLZ|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
769P MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzIdo5iUUN3ME2zNFAxKG6P MlvZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
NCI-H520 NXnseolHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zjXGlEPTB;M{CwNEBvVQ>? MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
DU145 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TSWWlEPTB;M{CwNEBvVQ>? NWPMR4drRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
K562 MnPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrLTWM2OD1|MECwJI5O NW\iWFh{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
U-937 MnLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTNyMECgcm0> M2HhblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
A204 M4PJeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTNyMEGgcm0> NInZdI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
DAOY M4e5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml64TWM2OD1|MECxJI5O MkHsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
SF-268 MmTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPJTWM2OD1|MECxJI5O NXXMWWNtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
SF-295 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzhTWM2OD1|MECxJI5O MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
SNB-19 NIf5OmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkT1TWM2OD1|MECxJI5O NVfKW2J3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
SNB-75 M2\5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4OzZmlEPTB;M{CwNUBvVQ>? NE\JRVA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
U373-MG MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PGZmlEPTB;M{CwNUBvVQ>? M33Z[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
786-O NVq4dXE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILqfG9KSzVyPUOwNFEhdk1? MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
A498 NUTUeZN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzEPFFsUUN3ME2zNFAyKG6P MoKzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
ACHN NHfxWnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\zXYxKSzVyPUOwNFEhdk1? Mk\uQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
EKVX NF\ienlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH32OmxKSzVyPUOwNFEhdk1? NFyxd4U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
H226 Mm[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTNyMEGgcm0> MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
H522 NYrnb2xDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvPOodKSzVyPUOwNFEhdk1? MlzUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
HeLa NIO3SoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDuWolKSzVyPUOwNFEhdk1? MojTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
SK-OV-3 M{LNS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;MN3pKUUN3ME2zNFAyKG6P NH;a[nc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
Ln Cap MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUjPfoxHUUN3ME2zNFAyKG6P NYLZT2t{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NVQ5QThpPkKzOlE1QDl6PD;hQi=>
PC3 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVH5e4V[UUN3ME2zNFAyKG6P MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
SNU-16 NWTzd4dLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTNyMEGgcm0> MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
FTC-133 M3nIS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPxXZdpUUN3ME2zNFAyKG6P M1mxdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
Ro82-W-1 M4nBN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3W2NGlEPTB;M{CwNUBvVQ>? MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
Daudi NX23dWVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmW5TWM2OD1|MECxJI5O MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
Jijoye NECzOW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLJc4JPUUN3ME2zNFAyKG6P MnHTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MUS4PVgoRjJ|NkG0PFk5RC:jPh?=
Jurkat MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjDUlhKSzVyPUOwNFEhdk1? NG\jdpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
J-82 M1ywXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTNyMEGgcm0> MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZzNEi5PEc,OjN4MUS4PVg9N2F-
TCC-SUP MnXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml6zTWM2OD1|MECxJI5O M3viT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NkG0PFk5Lz5{M{[xOFg6QDxxYU6=
BT-474 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLifXRuUUN3ME2zNFAyKG6P NFjTSmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
ZR-75-1 MnnVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV[0R2lWUUN3ME2zNFAyKG6P NEX5ZmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[xOFg6QCd-MkO2NVQ5QTh:L3G+
A375 M2DudGZ2dmO2aX;uJIF{e2G7 NWT0cWV{OiCqcoO= M4[xbWlvcGmkaYTpc44hd2ZiRWLLNkBqdiCqdX3hckBCOzd3IHPlcIx{KGijcnLvdolv\yCELWLBSkBXPjByRTDteZRidnRiYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4heGixc4Doc{1GWkt{IHzleoVtKGGodHXyJFIhcHK|IHL5JGNmdGyxbXnjd{BCenKjeWPjZY5VVSCYVFmgbY1i\2mwZzDhcoFtgXOrczygTWM2OCB;IECuNFA1KM7:TT6= NWXTVZNoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW5O|c6QDFpPkK1PVc4QThzPD;hQi=>
A375 NUjQZ3BqTnWwY4Tpc44h[XO|YYm= M334O2lvcGmkaYTpc44hd2ZiRWLLNkBqdiCqdX3hckBCOzd3IHPlcIx{KGijcnLvdolv\yCEUlHGJHY3ODCHIH31eIFvfCCjc4Pld5Nm\CCjczDk[YNz\WG|ZTDpckBxcG:|cHjvdplt[XSnZDDFVmszKGyndnXsd{whUUN3MDC9JFAvODB2IN88UU4> MnnZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh|N{[zNFYoRjJ6M{e2N|A3RC:jPh?=
COLO205 NXizfphzSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= M3X4R|Qh\GG7cx?= NVPJTplpSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDDU2xQOjB3IHPlcIx{KGijcnLvdolv\yCEUlHGJHY3ODCHL1SgcZV1[W62IH3lZZN2emWmIHHmeIVzKDRiZHH5d{whUUN3MDC9JFAvODF4IN88UU4> NVjBd5pGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwN|Q3OTVpPkOwNFM1PjF3PD;hQi=>
A375 NEPlO2pHfW6ldHnvckBie3OjeR?= MmPBNkBpenN? NXjFR|lYUW6qaXLpeIlwdiCxZjDFVmsyNzJiaX6gbJVu[W5iQUO3OUBk\WyuczDoZZJjd3KrbnegRk1TSUZiVk[wNGUhdXW2YX70JIF{e2W|c3XkJIF{KGSnY4LlZZNmKGmwIIDoc5NxcG9vUmPLJIxmfmWuIHHmeIVzKDJiaILzJIJ6KEOnbHzvcYlkeyCDcoLhfXNk[W6WTTDWWGkhcW2jZ3nu[{BidmGueYPpd{whUUN3MDC9JFAvODJizszNMi=> NI\xNHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm3O|k5OSd-MkW5O|c6QDF:L3G+
A375 MlrBSpVv[3Srb36gZZN{[Xl? MluxNkBpenN? NFHr[|VKdmirYnn0bY9vKG:oIFXST|EwOiCrbjDoeY1idiCDM{e1JINmdGy|IHjhdoJwemmwZzDCMXJCTiCYNkCwSUBufXSjboSgZZN{\XO|ZXSgZZMh\GWlcnXhd4UhcW5icHjvd5Bpdy2UU1ugcIV3\WxiYX\0[ZIhOiCqcoOgZpkhS2WubH;tbYN{KEG{cnH5V4NidlSPIG\UTUBqdWGpaX7nJIFv[Wy7c3nzMEBKSzVyIE2gNE4xOiEQvF2u NELtdVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm3O|k5OSd-MkW5O|c6QDF:L3G+
A375 MVPGeY5kfGmxbjDhd5NigQ>? MUTJcohq[mm2aX;uJI9nKEWUS{KgbY4hcHWvYX6gRVM4PSClZXzsd{Bp[XKkb4LpcochSlKDRjDWOlAxTSCvdYThcpQh[XO|ZYPz[YQh[XNiZHXjdoVie2ViaX6gdIhwe3Cqb4L5cIF1\WRiUmPLJIxmfmWuczygTWM2OCB;IECuNFIh|ryPLh?= M1[2T|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{e2N|A3Lz5{OEO3OlMxPjxxYU6=
HT-29 M4S3SGFvfGmycn;sbYZmemG2aY\lJIF{e2G7 M3TVRVQh\GG7cx?= MUfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiWLUK5JINmdGy|IHjhdoJwemmwZzDCVmFHKFZ4MEDFM2QhdXW2YX70JI1m[XO3cnXkJIFnfGW{IESg[IF6eyxiSVO1NEA:KDBwMEW5JO69VS5? NWjVRWdnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwN|Q3OTVpPkOwNFM1PjF3PD;hQi=>
HT-29 NV2w[YFWSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MWjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiWLUK5JINmdGy|IHjhdoJwemmwZzDCVmFHN0uUQWOgcZV1[W62LDDJR|UxKD1iMD6wOVkh|ryPLh?= NEC0dGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUe0PFA2OSd-Mkm3OFgxPTF:L3G+
A375 NGDVSolCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= NUHLZldDPzJiaILz MlLHRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCDM{e1JINmdGy|IHjhdoJwemmwZzDCMXJCTiCYNkCwSUBufXSjboSgZYZ1\XJiN{KgbJJ{KGK7IFPlcIxwdWmlczDBdpJigVOlYX7UUUBXXEliaX3h[4lv\yCjbnHsfZNqeyxiSVO1NEA:KDBwMEeg{txONg>? MmPDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7N{e5PFEoRjJ3OUe3PVgyRC:jPh?=
HT-29 MVnBdI9xfG:|aYOgZZN{[Xl? NVrRWWFEUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDIWE0zQSClZXzsd{Bp[XKkb4LpcochSlKDRj;LVmFUKG23dHHueEBjgSClYYPwZZNmKGGldHn2ZZRqd25iYYPzZZktKEmFNUCgQUAxNjB7NjFOwG0v NHHZd2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUe0PFA2OSd-Mkm3OFgxPTF:L3G+

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
cyclin B1 / cyclin D1 / p21; 

PubMed: 26725216     


Cells treated as above were collected for western blot for total cyclin B1, cyclin D1 and p21, and of phosphorylated, inactivated RB (S807/811; pRB). Western blot for pERK was done to verify SCH772984 inhibition; β-actin was the loading control.

pRSK / pERK / pAKT / pMEK; 

PubMed: 26725216     


Cells were treated for 4 or 24 hr with DMSO vehicle or SCH772984, then evaluated by western blot with phospho-specific antibodies for RSK (T395/S363; pRSK), MEK1/2 (S217/221; pMEK), AKT (S473; pAKT), and ERK (T202/Y204; pERK). Total RSK, ERK, AKT, MEK and β-actin were also analyzed. Data are representative of three independent experiments.

DUSP1 / DUSP4 / DUSP6; 

PubMed: 26725216     


Cells were treated for 4 or 24 hr with DMSO vehicle or SCH772984 for 72 hr and evaluated by western blot for DUSP1, DUSP4, DUSP6 and β-actin.

pCRAF(S338, S289, S296, S301); 

PubMed: 26725216     


Cells were treated for 4 or 24 hr with DMSO vehicle or SCH772984 for 72 hr and evaluated by western blot for pCRAF (S338), pCRAF (S289/296/301), total CRAF and β-actin.

Aurora B / ETS1 / ETS2; 

PubMed: 26725216     


Cells were treated with vehicle or SCH772984 for 7 days, then immunoblotted for Aurora B, MYC, ETS1 or ETS2, and β-actin. Data are representative of three independent experiments.

26725216
Growth inhibition assay
Cell viability; 

PubMed: 30118499     


NCI-H747, SW837, SW480, and SW620 cells were treated with the ERK inhibitor SCH772984 at indicated concentrations for 72 hours. Dimethyl sulfoxide (DMSO) (0.01%) was used as the control treatment. Each data point represents the mean of five replicates; error bars indicate one SD.

30118499
Immunofluorescence
TOMM20; 

PubMed: 30833752     


Mitochondrial morphologies of PDAC cells treated with SCH772984 (ERKi, 1 µM) for 24 h. Green, Anti-TOMM20; blue, DAPI; scale bar, 20 μm.

pERK1/2; 

PubMed: 30213106     


After treatment with 10 µM of the ERIK1/2 inhibitors, the expression of p-ERK1/2 protein in HeLa cells was detected using immunofluorescence (400×), bar = 50 μm.

30833752 30213106
In vivo SCH772984 induces tumor regressions in xenograft models at tolerated doses. SCH772984 effectively inhibites MAPK signaling and cell proliferation in BRAF or MEK inhibitor resistant models. [1]

Protocol

Kinase Assay:

[1]

- Collapse

ERK2 IMAP enzymatic assay:

SCH772984 is tested in 8 point dilution curves in duplicate against purified ERK2 or ERK1. The enzyme is added to the reaction plate. and incubated with the compound before adding a solution of substrate peptide and ATP. 14μl of diluted enzyme (0.3ng active ERK2 per reaction) is added to each well of a 384-well plate. The plates are gently shaken to mix the reagents and incubated for 45 minutes at room temperature. The reaction is stopped with 60μl of IMAP Binding Solution (1:2200 dilutions of IMAP beads in 1X Binding Buffer). The plates are incubated at room temperature for an additional 0.5 hours to allow complete binding of phosphopeptides to the IMAP beads. Plates are read on the LJL Analyst.
Cell Research:

[1]

- Collapse
  • Cell lines: BRAF-mutant or RAS-mutant tumor lines
  • Concentrations: ~10 μM
  • Incubation Time: 5 days
  • Method:

    Cell proliferation experiments are performed in a 96-well format (six replicates), and cells are plated at 4,000/well density. At 24 h after cell seeding, cells are treated with DMSO or 9 point IC50 dilution (0.001-10 μM) at 1% DMSO final for all concentrations. Viability is assayed on 5 days after dosing using ViaLight luminescence kit following the manufacturer’s recommendations. For cell line panel viability assay, cells are treated with SCH772984 for 4 days and assayed by CellTiterGlo luminescent cell viability assay.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: Nude mice
  • Dosages: 12.5 mg/kg, 25 mg/kg, 50 mg/kg
  • Administration: i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 14 mg/mL warmed (23.82 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
0.6mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 587.67
Formula

C33H33N9O2

CAS No. 942183-80-4
Storage powder
in solvent
Synonyms N/A
Smiles C1CN(CC1C(=O)NC2=CC3=C(C=C2)NN=C3C4=CC=NC=C4)CC(=O)N5CCN(CC5)C6=CC=C(C=C6)C7=NC=CC=N7

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to inhibit Erk1/2 by treating the mice with the inhibitor. by what kind of administration way and at what concentration could it be done?

  • Answer:

    SCH772984 can be administrated by I.P. The dosages can be used as: 12.5 mg/kg, 25 mg/kg, 50 mg/kg. For more detail information please find the paper below: http://cancerdiscovery.aacrjournals.org/content/3/7/742.full

ERK Signaling Pathway Map

Tags: buy SCH772984 | SCH772984 supplier | purchase SCH772984 | SCH772984 cost | SCH772984 manufacturer | order SCH772984 | SCH772984 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID